Shashi Kumar Nagaraj

Clinical areas of interest are chronic renal failure, dialysis, transplantation, hypertension, glomerulonephritis, nephrotic syndrome, urinary tract infections, congenital genitourinary anomalies, lupus nephritis,

Current Appointments & Affiliations

Professor of Pediatrics · 2021 - Present Pediatrics, Nephrology, Pediatrics

Chief, Division of Pediatric Nephrology · 2016 - Present Pediatrics, Nephrology, Pediatrics

Recent Publications

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

Journal Article Kidney International Reports · June 1, 2021 Introduction: Atypical hemolytic uremic syndrome (aHUS) is a rare, complex, multisystem disease of dysregulated complement activity, characterized by progressive thrombotic microangiopathy (TMA), acute kidney injury, and multiorgan dysfunction, which often ... Full text Cite

Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.

Journal Article Kidney Int · May 2021 Full text Link to item Cite

Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296.

Journal Article Kidney Int · December 2020 Full text Link to item Cite

View All Publications

Recent Grants

Single arm Study of ALXN1210 in Complement Inhibitor Treatment-Naive Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2017 - 2022

A PHASE 3, OPEN-LABEL, MULTICENTER STUDY OF ALXN1210 IN CHILDREN AND ADOLESCENTS WITH ATYPICAL HEMOLYTIC-UREMIC SYNDROME (aHUS)

Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2017 - 2020

Vifor PA21 Phaslyra

Clinical TrialPrincipal Investigator · Awarded by Vifor Fresenius Medical Care Renal Pharma · 2016 - 2019

View All Grants

Education, Training & Certifications

Kasturba Medical College (Manipal) · 1982 M.B.B.S.